Supplementary Data

Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807

David T. Chiena, Shadfar Bahrib, A. Katrin Szardeningsa, Joseph C. Walshc, Min-Ying Sub, William R. Shanklec, Arkadij Elizarova and Hartmuth C. Kolb∗

aSiemens Molecular Imaging, Inc., Culver City, CA, USA
bTu and Yuen Center for Functional Onco-Imaging, Department of Radiological Sciences, University of California Irvine, CA, USA
cShankle Clinic Memory and Cognitive Disorders Program, Hoag Neurosciences Institute, Newport Beach, CA, USA

Accepted 12 November 2012

Supplementary Table 1
Inclusion and exclusion criteria for the trial

Inclusion criteria
Participant has reached his or her 55th birthday at the time of informed consent
Participant provides written informed consent
Participant is capable of complying with study procedures
Participant is capable of communicating with study personnel
Participant understands and speaks English
Participant has at least an 8th Grade education
Participant has no significant hepatic or renal disease as defined by previous medical history and lab results

HC group
Participant has a low probability of being currently positive for AD as determined by a Mini Mental State Examination (MMSE ≥ 28)

AD group
Participant has a high probability of being currently positive for AD that is determined by a Mini Mental State Examination (MMSE < 24)

Exclusion Criteria
Female participant is pregnant or nursing
Participant has prior history of stroke or other condition of the head or neck that, in the Investigators opinion, might affect circulation to the head or image interpretation
Participant has other neurodegenerative disease that is associated with cognitive impairment or dementia
Participant has a medical condition that might be associated with elevated amyloid levels, such as amyloid angiopathy, familial amyloidosis, chronic kidney dialysis, Down’s syndrome
Participant has a history of significant cerebrovascular disease
Participant has previously received [F-18]T807 at any time
Participant has been involved in an investigative, radioactive research procedure within the past 14 days
Participant has any other condition or personal circumstance that, in the judgment of the Investigator, might interfere with the collection of complete data or data quality
Participant has a history in the last five years of significant prescription or non-prescription drug or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives

∗Correspondence to: Hartmuth C. Kolb, Siemens Molecular Imaging, Inc., 6100 Bristol Parkway, Culver City, CA 90230, USA. Tel.: +1 310 804 7324, Fax: +1 310 744 4879; E-mail: hckolb@me.com.

ISSN 1387-2677/13/$27.50 © 2013 – IOS Press and the authors. All rights reserved
Supplementary Figure 1. Example volume of interests (VOIs) of the left mesial temporal, left lateral temporal, and approximate area of the left hippocampus on an axial computed tomography (CT) slice.